论文部分内容阅读
目的:探讨RhoB在肾透明细胞癌中的表达及临床意义。方法:采用实时定量PCR、Westernblot和免疫组化方法检测RhoB在肾透明细胞癌组织中的表达情况。选取60例肾透明细胞癌组织标本,详细收集病人临床病理资料,通过免疫组化方法检测RhoB在肾透明细胞癌组织中的蛋白表达水平,并分析RhoB的蛋白水平与临床病理资料的关系。结果:与对应瘤旁肾组织相比,RhoB的mRNA及蛋白表达水平在肾透明细胞癌组织标本中明显降低;RhoB的蛋白表达水平在不同年龄、性别组间差异无统计学意义(P>0.05),而在肿瘤直径大小、T分期、临床分期和组织分级间差异有显著统计学差异(P<0.05)。结论:RhoB的表达降低可能在肾透明细胞癌的肿瘤发生中发挥作用,且其表达下降可能与肾透明细胞癌的恶性进展有关。
Objective: To investigate the expression of RhoB in renal clear cell carcinoma and its clinical significance. Methods: The expression of RhoB in renal clear cell carcinoma tissues was detected by real-time PCR, Western blot and immunohistochemistry. Sixty cases of clear cell renal cell carcinoma were collected. Clinicopathological data of the patients were collected. The protein expression of RhoB in renal clear cell carcinoma tissues was detected by immunohistochemistry. The relationship between RhoB protein and clinicopathological data was also analyzed. Results: The mRNA and protein expressions of RhoB in renal clear cell carcinoma tissues were significantly lower than those in corresponding adjacent tumor tissues. There was no significant difference in the expression of RhoB between different ages and gender groups (P> 0.05 ), But there was significant difference in tumor size, T stage, clinical stage and histological grade (P <0.05). Conclusion: The decreased expression of RhoB may play a role in the tumorigenesis of renal clear cell carcinoma, and the decreased expression of RhoB may be related to the malignant progression of renal clear cell carcinoma.